Peter Tyrer

786 citations

23 papers · 566 indexed · h-index 13

Impact in

Oncology top 10%
- CAR-T cell therapy research
- HER2/EGFR in Cancer Research
Pharmaceutical Science top 10%
- Advanced Drug Delivery Systems

Papers in ⓘ

Oncology 12
- CAR-T cell therapy research 5
- HER2/EGFR in Cancer Research 3
- Peptidase Inhibition and Analysis 2
Molecular Biology 6
- Cancer therapeutics and mechanisms 4

Co-authors: A. Ruth Foxwell (6 shared papers)Jennelle M. Kyd (3 shared papers)Allan W. Cripps (3 shared papers)Jacqueline I. Keenan (3 shared papers)Francesca Zammarchi (10 shared papers)Patrick H. van Berkel (9 shared papers)Michael A. Apicella (1 shared paper)John A. Hartley (9 shared papers)
Journals: Cancer Research (4 papers)Blood (3 papers)Molecular Cancer Therapeutics (2 papers)The International Journal of Biochemistry & Cell Biology (2 papers)Biochemical and Biophysical Research Communications (2 papers)
Partner nations: United Kingdom Australia New Zealand

In The Last Decade

Peter Tyrer

23 papers receiving 543 citations

Peers

Countries citing papers authored by Peter Tyrer

Since Specialization

Citations

This map shows the geographic impact of Peter Tyrer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Tyrer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Tyrer more than expected).

Fields of papers citing papers by Peter Tyrer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Tyrer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Tyrer. The network helps show where Peter Tyrer may publish in the future.

Co-authors

The 25 scholars most cited alongside Peter Tyrer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Peter Tyrer Line = papers co-authored together Peter Tyrer links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 23 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	ADCT-402, a PBD dimer–containing antibody drug conjugate targeting CD19-expressing malignancies Blood ·Francesca Zammarchi, Simon Corbett, Lauren Adams, Peter Tyrer, Konstantinos Kiakos, Narinder Janghra, Teresa Marafioti, Charles E. Britten, Carin E.G. Havenith, Simon Chivers, François D’Hooge, David G. Williams, Arnaud Tiberghien, Philip W. Howard, John A. Hartley, Patrick H. van Berkel	2018	118
2	ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer–Containing Antibody–Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies Molecular Cancer Therapeutics ·Michael Flynn, Francesca Zammarchi, Peter Tyrer, Ayse U. Akarca, Narinder Janghra, Charles E. Britten, Carin E.G. Havenith, Jean-Noel Levy, Arnaud Tiberghien, Luke A. Masterson, Conor S. Barry, François D’Hooge, Teresa Marafioti, Paul W.H.I. Parren, David G. Williams, Philip W. Howard, Patrick H. van Berkel, John A. Hartley	2016	85
3	Microbial Pattern Recognition Receptors Mediate M-Cell Uptake of a Gram-Negative Bacterium Infection and Immunity ·Peter Tyrer, A. Ruth Foxwell, Allan W. Cripps, Michael A. Apicella, Jennelle M. Kyd	2005	77
4	Validation and quantitation of an in vitro M-cell model Biochemical and Biophysical Research Communications ·Peter Tyrer, A. Ruth Foxwell, Jennelle M. Kyd, Matthew Harvey, Phillip Sizer, Allan W. Cripps	2002	48
5	Escherichia coli-derived outer membrane vesicles are genotoxic to human enterocyte-like cells Infectious Agents and Cancer ·Peter Tyrer, Frank Frizelle, Jacqueline I. Keenan	2014	38
6	Receptor mediated targeting of M-cells Vaccine ·Peter Tyrer, A. Ruth Foxwell, Jennelle M. Kyd, Diana C. Otczyk, Allan W. Cripps	2007	35
7	The measurement of engagement in the homeless mentally ill: the Homeless Engagement and Acceptance Scale – HEAS Psychological Medicine ·Minji Park, Peter Tyrer, E. Elsworth, Jack T Fox, Obioha C. Ukoumunne, Alison M. Macdonald	2002	33
8	The risk of pharmacological dependence with buspirone. PubMed ·Peter Tyrer, Siobhán Murphy, R T Owen	1985	22
9	Effects of bacterial products on enterocyte–macrophage interactions in vitro Biochemical and Biophysical Research Communications ·Peter Tyrer, Elaine Bean, A. Ruth Foxwell, Paul Pavli	2011	15
10	ADCT-502, a novel pyrrolobenzodiazepine (PBD)-based antibody–drug conjugate (ADC) targeting low HER2-expressing solid cancers European Journal of Cancer ·Francesca Zammarchi, Simon Chivers, David G. Williams, Lauren Adams, Maria Mellinas‐Gomez, Peter Tyrer, Simon Corbett, François D’Hooge, Sandamali Dissanayake, Simone Sims, Karin Havenith, Philip W. Howard, J.A. Hartley, Patrick H. van Berkel	2016	14
11	Protein-bound 3,4-dihydroxy-phenylanine (DOPA), a redox-active product of protein oxidation, as a trigger for antioxidant defences The International Journal of Biochemistry & Cell Biology ·Michelle Nelson, A. Ruth Foxwell, Peter Tyrer, Roger T. Dean	2006	13
12	Influences of enteral nutrition upon CEACAM6 expression by intestinal epithelial cells Innate Immunity ·Jacqueline I. Keenan, Elizabeth M. Hooper, Peter Tyrer, Andrew S. Day	2013	12
13	hLL2-Cys-PBD, a New Site-Specifically Conjugated, Pyrrolobenzodiazepine (PBD) Dimer-Based Antibody Drug Conjugate (ADC) Targeting CD22-Expressing B-Cell Malignancies. Blood ·Francesca Zammarchi, Simon Corbett, Lauren Adams, Maria Mellinas‐Gomez, Peter Tyrer, Sandamali Dissanayake, Simone Sims, Karin Havenith, Simon Chivers, David G Willimas, Philip W. Howard, John A. Hartley, Patrick van Berkel	2016	12
14	Selection of Patients for Clinical Trials BMJ ·Peter Tyrer	1973	8
15	ADCT-602, a Novel PBD Dimer–containing Antibody–Drug Conjugate for Treating CD22-positive Hematologic Malignancies Molecular Cancer Therapeutics ·Francesca Zammarchi, Karin Havenith, Nikoleta Sachini, Narinder Janghra, Simon Chivers, Esohe Idusogie, Eugenio Gaudio, Chiara Tarantelli, François Bertelli, Kathleen Santos, Peter Tyrer, Simon Corbett, Filippo Spriano, Gaetanina Golino, Luciano Cascione, Francesco Bertoni, John A. Hartley, Patrick H. van Berkel	2024	6
16	Human lactoferrin increases Helicobacter pylori internalisation into AGS cells World Journal of Microbiology and Biotechnology ·Dorien S. Coray, Jack A. Heinemann, Peter Tyrer, Jacqueline I. Keenan	2012	6
17	Mechanistic and Pharmacodynamic Studies of Adct-301, a Pyrrolobenzodiazepine (PBD) Dimer-Containing Antibody Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies Blood ·Michael Flynn, Patrick H. van Berkel, Francesca Zammarchi, Peter Tyrer, Ayse U. Akarca, Narinder Janghra, Vishvesh Shende, J. Linares, Teresa Marafioti, David G. Williams, Philip W. Howard, John A. Hartley	2015	6
18	Radical sequestration by protein-bound 3,4-dihydroxyphenylalanine The International Journal of Biochemistry & Cell Biology ·Michelle Nelson, A. Ruth Foxwell, Peter Tyrer, Roger T. Dean	2010	4
19	Abstract 52: Mechanistic and benchmarking studies of ADCT-502, a pyrrolobenzodiazepine (PBD) dimer-containing antibody-drug conjugate (ADC) targeting HER2-expressing solid tumors Cancer Research ·Francesca Zammarchi, Halla W. Reinert, Narinder Janghra, Simon Corbett, Maria Mellinas‐Gomez, Sajidah Chowdhury, Neha Arora, Peter Tyrer, François Bertelli, David G. Williams, Philip W. Howard, John A. Hartley, Patrick H. van Berkel	2017	4
20	Abstract 2792A: Preclinical activity of ADCT-601, a novel pyrrolobenzodiazepine (PBD) dimer-based antibody-drug conjugate (ADC) targeting AXL-expressing tumors Cancer Research ·Francesca Zammarchi, Karin Havenith, Simon Chivers, Paul W. Hogg, Charlie Britten, Sandamali Dissanayake, Peter Tyrer, François Bertelli, Ian Hutchinson, Luke A. Masterson, Phil W. Howard, John A. Hartley, Patrick H. van Berkel	2018	4

About Peter Tyrer

Peter Tyrer is a scholar working on Oncology, Molecular Biology, Neurology, Endocrinology and Organic Chemistry, having authored 23 papers that have together received 566 indexed citations. Recurring topics across this work include CAR-T cell therapy research (5 papers), Escherichia coli research studies (5 papers), Cancer therapeutics and mechanisms (4 papers), Synthesis and pharmacology of benzodiazepine derivatives (4 papers), Neuroblastoma Research and Treatments (4 papers), HER2/EGFR in Cancer Research (3 papers), Immune Response and Inflammation (3 papers) and Peptidase Inhibition and Analysis (2 papers). The work is most often cited by research in Oncology (239 citations), Pharmaceutical Science (36 citations), Immunology (122 citations), Radiology, Nuclear Medicine and Imaging (124 citations) and Microbiology (31 citations). Peter Tyrer has collaborated with scholars based in United Kingdom, Australia and New Zealand. Frequent co-authors include A. Ruth Foxwell, Jennelle M. Kyd, Allan W. Cripps, Jacqueline I. Keenan, Francesca Zammarchi, Patrick H. van Berkel, Michael A. Apicella, John A. Hartley, David G. Williams and Philip W. Howard. Their work appears in journals such as Cancer Research, Blood, Molecular Cancer Therapeutics, The International Journal of Biochemistry & Cell Biology and Biochemical and Biophysical Research Communications.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact